| scholarly article | Q13442814 |
| P2093 | author name string | Chih-Li Lin | |
| Chien-Ning Huang | |||
| Hsin-Hua Li | |||
| P2860 | cites work | Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes | Q24606835 |
| The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease | Q26777969 | ||
| Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases | Q27009984 | ||
| Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism | Q28203757 | ||
| AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location | Q28243750 | ||
| AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus | Q28254114 | ||
| Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity | Q28276393 | ||
| Statins Promote the Degradation of Extracellular Amyloid β-Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion | Q28294279 | ||
| AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism | Q29617261 | ||
| Amyloid precursor protein trafficking, processing, and function | Q29617429 | ||
| Abnormal processing of multiple proteins in Alzheimer disease | Q30450830 | ||
| Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis | Q30457367 | ||
| Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors | Q30814231 | ||
| Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells | Q33566705 | ||
| ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. | Q33733667 | ||
| The evolving role of statins in the management of atherosclerosis | Q33818141 | ||
| Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 | ||
| The intersection of amyloid beta and tau at synapses in Alzheimer's disease | Q34054680 | ||
| Clinically relevant differences between the statins: implications for therapeutic selection | Q34093408 | ||
| Amyloidosis and Alzheimer's disease | Q34161041 | ||
| The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. | Q34289101 | ||
| Statins and the risk of dementia | Q34511970 | ||
| Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons | Q34663462 | ||
| Statins: mechanism of action and effects. | Q34687736 | ||
| Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies | Q34991103 | ||
| Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models | Q35053059 | ||
| A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease | Q35144361 | ||
| Cholesterol metabolism and homeostasis in the brain | Q35252263 | ||
| Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations | Q35642416 | ||
| Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 | ||
| Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. | Q35897595 | ||
| Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction | Q35914692 | ||
| Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity | Q35941717 | ||
| The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease | Q36381073 | ||
| Cholesterol sensing, trafficking, and esterification. | Q36497100 | ||
| Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease | Q36599797 | ||
| A hundred years of Alzheimer's disease research | Q36610336 | ||
| The GSK3 hypothesis of Alzheimer's disease | Q37035378 | ||
| DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells | Q37275631 | ||
| Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity | Q37339912 | ||
| The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease | Q37515489 | ||
| AMPK in Health and Disease | Q37543855 | ||
| Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease | Q37650830 | ||
| Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease | Q37829752 | ||
| AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan | Q37856788 | ||
| Cholesterol metabolism in neurons and astrocytes. | Q37899491 | ||
| Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised | Q37971458 | ||
| Peripheral cholesterol, metabolic disorders and Alzheimer's disease | Q37971612 | ||
| Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver X receptors | Q38024222 | ||
| Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease | Q38230391 | ||
| CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. | Q38262127 | ||
| miR-302 Attenuates Amyloid-β-Induced Neurotoxicity through Activation of Akt Signaling | Q38793126 | ||
| Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior? | Q38896297 | ||
| Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis | Q39061232 | ||
| Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease | Q39109470 | ||
| Interplay between cholesterol and homocysteine in the exacerbation of amyloid-β toxicity in human neuroblastoma cells | Q39127356 | ||
| Statins reduce amyloid-beta production through inhibition of protein isoprenylation | Q40103529 | ||
| Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. | Q40457061 | ||
| Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease | Q41428334 | ||
| Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance | Q42044617 | ||
| Long-term use of statins reduces the risk of hospitalization for dementia | Q44531975 | ||
| Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects | Q44826850 | ||
| Selective benefits of simvastatin in bitransgenic APPSwe,Ind/TGF-β1 mice | Q45789765 | ||
| Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model | Q45876904 | ||
| Why lipids are important for Alzheimer disease? | Q46179010 | ||
| Statins activate AMP-activated protein kinase in vitro and in vivo | Q46230916 | ||
| Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up | Q46663053 | ||
| Regulatory effects of simvastatin and apoJ on APP processing and amyloid-β clearance in blood-brain barrier endothelial cells | Q47754619 | ||
| Mevastatin promotes neuronal survival against Aβ-induced neurotoxicity through AMPK activation | Q47907500 | ||
| Simvastatin prevents β-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through α7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate | Q48140368 | ||
| Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease | Q48201019 | ||
| Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems. | Q48253206 | ||
| Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies | Q48601285 | ||
| Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. | Q51029182 | ||
| Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease | Q57620860 | ||
| 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E | Q88263238 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurotoxicity | Q3338704 |
| P304 | page(s) | 198-206 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Neural Regeneration Research | Q15710164 |
| P1476 | title | Neuroprotective effects of statins against amyloid β-induced neurotoxicity. | |
| P478 | volume | 13 |
| Q89909412 | Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters |
| Q91542980 | Autophagy induction in the treatment of Alzheimer's disease |
| Q64894894 | Search of Neuroprotective Polyphenols Using the "Overlay" Isolation Method. |
| Q91977386 | [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action |
Search more.